| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -5,182 | -3,482 |
| Share-based compensation expense | 1,517 | 1,022 |
| Depreciation | 4 | 3 |
| Amortization of operating lease right-of-use assets | 72 | 48 |
| Accounts receivable | -228 | -226 |
| Inventory | -58 | -53 |
| Prepaid research and development | -37 | -37 |
| Prepaid expenses and other current assets | -117 | -101 |
| Deferred financing costs | 0 | 0 |
| Long-term prepaid contracts | -213 | -137 |
| Accounts payable | -139 | -100 |
| Operating lease liability | -70 | -45 |
| Accrued and other current liabilities | 106 | 342 |
| Deferred revenue | 128 | 149 |
| Insurance premium financing payable-Insurance Premium Financing Payable | -253 | -190 |
| Net cash used in operating activities | -3,164 | -1,699 |
| Proceeds from convertible debt related party-Related Party | 0 | 0 |
| Proceeds from issuance of common stock | 2,000 | 0 |
| Proceeds from exercise of warrants | 0 | - |
| Payments on convertible debt - related party-Related Party | 0 | - |
| Net cash provided by financing activities | 2,000 | 0 |
| Effect of exchange rate changes on cash | -3 | -1 |
| Net decrease in cash and cash equivalents | -1,167 | -1,700 |
| Cash and cash equivalents at beginning of period | 2,486 | - |
| Cash and cash equivalents at end of period | 1,319 | - |
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)